Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Core Insights - Coherus Oncology is set to present CHS-114, an anti-CCR8 cytolytic antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5-9, 2025 [1][2] - CHS-114 has shown selective intratumoral Treg depletion and favorable immune remodeling in patients with advanced solid tumors [2] - The company is focused on enhancing its immuno-oncology pipeline, which includes multiple antibody candidates aimed at improving patient outcomes in cancer treatment [4] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising proprietary pipeline [3] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and explore new indications in combination with its pipeline candidates and partners [3] - Coherus' pipeline includes candidates targeting various cancers, including liver, lung, head & neck, colorectal, gastric, and esophageal cancers [4] Upcoming Events - CHS-114 will be featured in a live webinar series titled "Targets for Cancer IO: A Deep Dive" on October 22, 2025, discussing the therapeutic target CCR8 and its implications in cancer treatment [2][8] - The webinar will include discussions on the mechanisms and clinical results of anti-CCR8 antibodies, highlighting the latest advances in this area [2]